Inmaculada Boyano

Inmaculada Boyano

Auto-generated profile, based on publicly available information

Inmaculada Boyano

Servicio de Geriatría, Hospital Universitario de Móstoles, Madrid, España

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Closed access
JOJavier Olazarán
Javier Olazarán
ARAna Ramos
Ana Ramos
IBInmaculada Boyano
Inmaculada Boyano
EAEva Alfayate
Eva Alfayate
MVMeritxell Valentí
Meritxell Valentí
JÁJuan Álvarez-Linera
Juan Álvarez-Linera
A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia (r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease (r = .33), cortical infarction (r = .20), and antiaggregant or anticoagulant treatment duration (r = .20). Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.

11 August 2014 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JOJavier Olazarán
Javier Olazarán
BGBelén González
Belén González
EOEmma Osa-Ruiz
Emma Osa-Ruiz
SFSilvia Felipe-Ruiz
Silvia Felipe-Ruiz
IBInmaculada Boyano
Inmaculada Boyano
PMPablo Martínez-Martín
Pablo Martínez-Martín
We conducted a randomized, cross-over trial to investigate the feasibility, safety, and motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technique in patients with Alzheimer's disease (AD). Neuropostural optimization (NPO) and sham protocol were administered to 60 patients from the nursing home and day care units of the Alzheimer Center Reina Sofía Foundation. The mean age was 84.1 (SD 7.9) years and 86.7% of the subjects were female. Motor measures were collected at baseline (T1), immediately (T2), seven (T3), and 11 days (T4) after treatment and, following cross-over, immediately (T5), seven (T6), and 11 (T7) days after treatment. Close safety surveillance was conducted from seven days before T1 to the end of the study (T7), with total study duration of 35 days. Wilcoxon test was utilized in the efficacy analysis, considering T1 and T5 as independent baseline assessments and using a threshold of p < 0.05 (corrected) for statistical significance. The NPO protocol was easily administered and well accepted by the participants. Axial movements improved at T3 and T4 after NPO and at T2 after sham NPO, but no significant effects were observed in axial movements in the second phase of the trial. The effects of NPO in gait performance were not consistent. There were six falls between T2 and T7, but only two of them occurred in patients who had received NPO. In light of safety and feasibility of REAC, a trial with the more intense neuropsycho-physical optimization protocol is warranted.

1 October 2018 in Neurología
Verified
Journal Article
Open access
IBI. Boyano
I. Boyano
NBN. Bravo
N. Bravo
JMJ. Miranda
J. Miranda
PGP. Gil-Gregorio
P. Gil-Gregorio
JOJ. Olazarán
J. Olazarán
Introduction: Brain microbleeds (BMB) are haemosiderin deposits contained within macrophages, which are displayed as hypointense images in some T2-weighted magnetic resonance imaging sequences. There are still many questions to be answered about the pathophysiology and clinical relevance of BMB. Development: We conducted a literature review of the main epidemiological, clinical, and anatomical pathology studies of BMB performed in the general population, in patients at risk of or already suffering from a vascular disease, and in patients with cognitive impairment. We analysed the prevalence of BMB, risk factors, and potential pathophysiological mechanisms and clinical implications. Conclusions: The prevalence of BMB is highly variable (3%-27% in the general population, 6%-80% in patients with vascular risk factors or vascular disease, and 16%-45% in patients with cognitive impairment). BMB are associated with ageing, Alzheimer disease (AD), and in particular haemorrhagic or ischaemic cerebrovascular disease. The pathological substrate of BMB is either lipohyalinosis (subcortical BMB) or cerebral amyloid angiopathy (lobar BMB). BMB exacerbate cognitive impairment, possibly through cortical-subcortical and intracortical disconnection, and increase the risk of death, mostly due to vascular causes. BMB also increase the risk of cerebral haemorrhage, particularly in patients with multiple lobar BMB (probable erebral amyloid angiopathy). Therefore, anticoagulant treatment may be contraindicated in these patients. In patients with lower risk of bleeding, the new oral anticoagulants and the combination of clinical and magnetic resonance imaging follow-up could be helpful in the decision-making process. (c) 2016 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.

7 May 2018 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Open access
IBInmaculada Boyano
Inmaculada Boyano
ARAna Ramos
Ana Ramos
JLJorge López-Alvarez
Jorge López-Alvarez
CMCarolina Mendoza-Rebolledo
Carolina Mendoza-Rebolledo
EOEmma Osa-Ruiz
Emma Osa-Ruiz
JOJavier Olazarán
Javier Olazarán
We conducted a longitudinal study to explore the clinical and pathological correlates of cerebral microbleeds (CMBs) in institutionalized patients with dementia. Clinical and magnetic resonance imaging (MRI) data were extracted from 182 nursing home patients (mean age [standard deviation]: 81.3 [6.9], 78.0% female, and 83.4% moderate to severe dementia), which were divided according to the CMBs number and location. One-year follow-up data were obtained from 153 patients, and postmortem pathological diagnosis was available in 40 patients. Cerebral microbleeds were observed in 42.9% of patients and were associated with MRI ischemic lesions (P < .0005). In the adjusted analysis, lobar CMB predicted worsening of parkinsonism (standardized β: 0.43) and gait (standardized β: 0.24). A pathological diagnosis of Alzheimer’s disease was less frequent in the brains of patients with lobar and deep CMB (33.3% vs 85.3%; P < .05). Cerebral microbleeds were linked to cerebrovascular disease and predicted motor deterioration in institutionalized people with advanced dementia.